Research analysts at The Goldman Sachs Group initiated coverage on shares of Olink Holding AB (publ) (NASDAQ:OLK) in a report released on Monday, The Fly reports. The firm set a “neutral” rating on the stock.
Separately, BTIG Research started coverage on Olink Holding AB (publ) in a report on Monday. They set a “buy” rating and a $44.00 price target for the company.
NASDAQ OLK opened at $37.50 on Monday. Olink Holding AB has a 52 week low of $28.97 and a 52 week high of $42.20.
Olink Holding AB (publ) Company Profile
Olink Holding AB (publ) provides products and services for human protein biomarker discovery worldwide. Its Olink Explore product line include protein biomarker assays primarily for cardiovascular and metabolic diseases, oncology, neurology, and inflammation; Olink Target product line comprise human protein biomarkers for monitoring immune system and downstream applications in clinical trials; and Olink Focus product line consists of custom developed solutions for customers that have identified a small number of proteins of interest, or a protein signature.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Olink Holding AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olink Holding AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.